Search

On February 24, 2022, a war began within the Ukrainian borders. At least 3.0 million Ukrainian inhabitants have already fled the country. Critical infrastructure, including hospitals, has been damaged. Children with cancer were urgently transported to foreign countries, in an effort to minimize interruption of their life-saving treatments. Most adults did not have that option. War breeds cancer-delaying diagnosis, preventing treatment, and increasing risk. We project that a modest delay in care of only 4 months for five prevalent types of cancer will lead to an excess of over 3,600 cancer deaths in the subsequent years. It is critical that we establish plans to mitigate that risk as soon as possible., Competing Interests: Christian CaglevicConsulting or Advisory Role: MSD, RocheSpeakers' Bureau: MSD, RocheResearch Funding: Merck Sharp & Dohme, Medivation, AstraZeneca, Roche, Astellas Pharma, Bristol Myers Squibb, GlaxoSmithKline, Athenex Christian RolfoConsulting or Advisory Role: Archer, Inivata, Merck Serono, Bristol Myers Squibb, Novartis, Boston Pharmaceuticals, Eisai, Mirati TherapeuticsSpeakers' Bureau: MSD, AstraZeneca, Guardant Health, Roche Molecular DiagnosticsResearch Funding: Lung Cancer Research FoundationTravel, Accommodations, Expenses: AstraZenecaUncompensated Relationships: Guardant Health Ignacio Gil-BazoConsulting or Advisory Role: MSD Oncology, Lilly, AstraZeneca Spain, Bristol Myers Squibb/CelgeneSpeakers' Bureau: MSD Oncology, AstraZeneca, Bristol Myers Squibb/Celgene, Roche, AmgenTravel, Accommodations, Expenses: MSD Oncology, Lilly Andrés CardonaHonoraria: Bristol Myers Squibb, Roche, Boehringer Ingelheim, AbbVie, Merck Sharp & Dohme, CelldexConsulting or Advisory Role: Roche, Merck Sharp & Dohme, Novartis, AstraZeneca, Bristol Myers Squibb, Foundation Medicine, Boehringer Ingelheim, Foundation for Clinical and Applied Cancer Research (FICMAC)Speakers' Bureau: Merck Sharp & Dohme, Roche, Bristol Myers Squibb, Novartis, Foundation for Clinical and Applied Cancer Research (FICMAC), Foundation MedicineTravel, Accommodations, Expenses: Merck Sharp & Dohme, Bristol Myers Squibb, Roche, Boehringer Ingelheim, Foundation Medicine Fred R. HirschConsulting or Advisory Role: AstraZeneca, Genentech, Merck, Bristol Myers Squibb, Novartis, Amgen, Oncocyte, Sanofi/Regeneron, Daiichi Sankyo/UCB Japan, Nectin Therapeutics, Novocure, Blueprint MedicinesPatents, Royalties, Other Intellectual Property: EGFR FISH and IHC for prediction of outcome in patients treated with EGFR inhibitors (Inst)Expert Testimony: Gerson Lehrman Group David R. GandaraHonoraria: Merck, AmgenConsulting or Advisory Role: AstraZeneca (Inst), Guardant Health (Inst), OncoCyte (Inst), IO Biotech (Inst), Roche/Genentech (Inst), Lilly, Novartis, Adagene (Inst), OncoHost (Inst), Ocean Genomics (Inst), Daiichi Sankyo Alliance, SanofiResearch Funding: Merck (Inst), Amgen (Inst), Genentech (Inst), AstraZeneca (Inst) Gilberto MorganConsulting or Advisory Role: Novartis Silvia NovelloConsulting or Advisory Role: SanofiSpeakers' Bureau: AstraZeneca, MSD, Bristol Myers Squibb, Roche, Pfizer, Lilly, Takeda, AbbVie, Boehringer Ingelheim, Bayer, Amgen, Beigene, Novartis, Janssen Marina-Chiara GarassinoHonoraria: MSD Oncology, AstraZeneca/MedImmune, GlaxoSmithKline, Takeda, Roche, Bristol Myers SquibbConsulting or Advisory Role: Bristol Myers Squibb, MSD, AstraZeneca, Novartis, Takeda, Roche, Tiziana Life Sciences, Sanofi, Celgene, Daiiki Sankyo, Inivata, Incyte, Pfizer, Seattle Genetics, Lilly, GlaxoSmithKline, Bayer, Blueprint Medicines, Janssen, RegeneronSpeakers' Bureau: AstraZeneca, Takeda, MSD Oncology, Celgene, Incyte, Roche, Bristol Myers Squibb, Otsuka, LillyResearch Funding: Bristol Myers Squibb (Inst), MSD (Inst), Roche/Genentech (Inst), AstraZeneca/MedImmune (Inst), Pfizer (Inst), GlaxoSmithKline (Inst), Novartis (Inst), Merck (Inst), Incyte (Inst), Takeda (Inst), Spectrum Pharmaceuticals (Inst), Blueprint Medicines (Inst), Lilly (Inst), AstraZeneca (Inst), Ipsen (Inst), Janssen (Inst), Exelixis (Inst), MedImmune (Inst), Sanofi (Inst), Amgen (Inst)Travel, Accommodations, Expenses: Pfizer, Roche, AstraZeneca Giannis MountziosHonoraria: Roche, Boehringer Ingelheim, AstraZeneca, MSD, BMS GmbH & Co KG, Novartis, Amgen, TakedaConsulting or Advisory Role: Roche, Astra Zeneca Greece, MSD, Amgen, Novartis, BMS GmbH & Co KG, TakedaSpeakers' Bureau: AstraZenecaTravel, Accommodations, Expenses: AstraZeneca, Ipsen, MSD, Roche, Novartis, BMS GmbH & Co KG Natasha B. LeighlResearch Funding: Roche Canada (Inst), Guardant Health (Inst), MSD (Inst), EMD Serono (Inst), Lilly (Inst), AstraZeneca Canada (Inst), Takeda (Inst), Amgen (Inst), Bayer (Inst), MSD Oncology (Inst)Travel, Accommodations, Expenses: Merck Sharp & Dohme Oscar ArrietaHonoraria: Pfizer, AstraZeneca, Boehringer Ingelheim, RocheConsulting or Advisory Role: AstraZeneca, Roche, Lilly, Merck, Bristol Myers SquibbResearch Funding: Roche (Inst), BMS (Inst), Merck (Inst), AstraZeneca (Inst)Travel, Accommodations, Expenses: Lilly Alfredo AddeoConsulting or Advisory Role: Roche, AstraZeneca/MedImmune, Bristol Myers Squibb Foundation, MSD Oncology, Pfizer, Novartis, Astellas Pharma, Amgen, LillySpeakers' Bureau: Lilly, AstraZeneca/MedImmuneTravel, Accommodations, Expenses: Roche, Takeda Stephen V. LiuConsulting or Advisory Role: Genentech, Lilly, Bristol Myers Squibb, AstraZeneca, Takeda, Regeneron, Guardant Health, Janssen Oncology, MSD Oncology, Jazz Pharmaceuticals, Blueprint Medicines, Daiichi Sankyo/UCB Japan, BeiGene, Amgen, Turning Point Therapeutics, Elevation Oncology, Novartis, Eisai, Bayer, Gilead Sciences, SanofiResearch Funding: Genentech/Roche (Inst), Pfizer (Inst), Bayer (Inst), Merck (Inst), Blueprint Medicines (Inst), Lilly (Inst), Rain Therapeutics (Inst), Alkermes (Inst), Bristol Myers Squibb (Inst), Turning Point Therapeutics (Inst), RAPT Therapeutics (Inst), Merus (Inst), Elevation Oncology (Inst), Nuvalent, Inc (Inst), Gilead Sciences (Inst)Travel, Accommodations, Expenses: Caris Life Sciences Luis CorralesConsulting or Advisory Role: AstraZeneca, Roche, MSD Oncology, PfizerSpeakers' Bureau: Roche, AstraZeneca, MSD OncologyResearch Funding: RocheTravel, Accommodations, Expenses: Roche, AstraZeneca, MSD Oncology Vivek SubbiahConsulting or Advisory Role: MedImmune, Helsinn Therapeutics, Loxo, R-Pharm, QED TherapeuticsResearch Funding: Novartis (Inst), GlaxoSmithKline (Inst), NanoCarrier (Inst), Northwest Biotherapeutics (Inst), Genentech/Roche (Inst), Berg Pharma (Inst), Bayer (Inst), Incyte (Inst), Fujifilm (Inst), PharmaMar (Inst), D3 Oncology Solutions (Inst), Pfizer (Inst), Amgen (Inst), AbbVie (Inst), Multivir (Inst), Blueprint Medicines (Inst), LOXO (Inst), Vegenics (Inst), Takeda (Inst), Alfasigma (Inst), Agensys (Inst), Idera (Inst), Boston Biomedical (Inst), Inhibrx (Inst), Exelixis (Inst), Turning Point Therapeutics (Inst)Travel, Accommodations, Expenses: PharmaMar, Bayer, Novartis, Helsinn TherapeuticsOther Relationship: Medscape Franz Villarroel-EspindolaConsulting or Advisory Role: Ilico GeneticsResearch Funding: Gebrax-Chile Laboratory & Gebrax Cia Ltda Ricardo MoralesConsulting or Advisory Role: Pfizer Luis RaezResearch Funding: Genentech/Roche (Inst), Merck Serono (Inst), Boehringer Ingelheim (Inst), Novartis (Inst), Pfizer (Inst), Syndax (Inst), Loxo (Inst), Merck (Inst), Bristol Myers Squibb (Inst), Guardant Health (Inst), Heat Biologics (Inst), Amgen (Inst), Calithera Biosciences (Inst), Daiichi Sankyo/UCB Japan (Inst), NantHealth (Inst) Jorge AlatorreHonoraria: Bristol Myers Squibb (Mexico), AstraZeneca, Roche/GenentechConsulting or Advisory Role: MSD Oncology, AstraZeneca, Roche/Genentech, Bristol Myers Squibb, NovartisSpeakers' Bureau: Roche/Genentech, AstraZeneca, MSDTravel, Accommodations, Expenses: AstraZeneca, Roche Edgardo SantosSpeakers' Bureau: Genentech/Roche, Pfizer, Amgen, Boehringer Ingelheim, Merck, Novartis, AstraZeneca, Takeda, Genzyme, Lilly, Astellas Pharma, G1 Therapeutics, Regeneron Luis UbillosHonoraria: Tecnofarma, Fármaco UruguayoConsulting or Advisory Role: Tecnofarma, Roche, Fármaco Uruguayo, PfizerSpeakers' Bureau: Tecnofarma, RocheTravel, Accommodations, Expenses: GlaxoSmithKline, Roche, Pfizer, AstraZeneca, Tecnofarma Daniel S.W. TanHonoraria: Bristol Myers Squibb, Takeda, Novartis, Roche, PfizerConsulting or Advisory Role: Novartis, Merck, Loxo, AstraZeneca, Roche, Pfizer, C4 TherapeuticsResearch Funding: Novartis (Inst), GlaxoSmithKline (Inst), AstraZeneca (Inst)Travel, Accommodations, Expenses: Pfizer, Boehringer Ingelheim, Roche Christoph ZielinskiHonoraria: Athenex, MSD, Roche, AstraZeneca, ImugeneConsulting or Advisory Role: Roche (Inst), Merck Sharp & Dohme (Inst), Imugene, Fibrogen (Inst), AstraZeneca (Inst), Servier (Inst), Athenex, Lilly (Inst), Amgen (Inst), Bristol Myers Squibb (Inst)Research Funding: Pfizer (Inst), Bristol Myers Squibb (Inst), AstraZeneca (Inst), Merck Sharp & Dohme (Inst)Patents, Royalties, Other Intellectual Property: Patent Property, ImugeneNo other potential conflicts of interest were reported.